DaCapo Brainscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

DaCapo Brainscience is a private, preclinical-stage biotech founded in 2016 and based in Boston/Cambridge, MA. The company has built a proprietary, human biology-focused discovery platform designed to identify and validate novel targets linked to disease progression in neurodegenerative disorders. DaCapo has identified its first proprietary target for sporadic Parkinson's disease and is currently screening brain-penetrant small molecules, positioning it to address a significant unmet need in a large patient population. The company's work is supported by a grant from The Michael J. Fox Foundation.

Parkinson's DiseaseNeurodegenerative Diseases

Technology Platform

Integrated discovery platform combining human data analytics, network biology, human iPSC-derived mature/aged CNS models, and phenotypic screening to identify and validate novel targets and drug candidates for neurodegenerative disease progression.

Opportunities

The primary opportunity is addressing the massive unmet need for disease-modifying therapies in sporadic Parkinson's disease, a multi-billion dollar market.

DaCapo's platform and biomarker strategy could enable precision medicine approaches, leading to more efficient clinical trials and a targeted therapy for a significant patient subset.

Success in Parkinson's would validate the platform for expansion into other large neurodegenerative indications like Alzheimer's and ALS.

Risk Factors

Key risks include the unproven predictive validity of the integrated discovery platform for clinical outcomes, the inherent scientific challenge of modeling complex human neurodegeneration in vitro, and the significant capital requirements to advance to the clinic in a competitive funding environment.

The novel biology of its lead target carries standard drug development risks of efficacy and safety.

Competitive Landscape

DaCapo operates in the highly competitive neurodegenerative disease space, competing with large pharmaceutical companies and numerous biotechs pursuing a range of targets (e.g., alpha-synuclein, GCase, LRRK2, inflammation). Its differentiation lies in its focus on novel progression-linked targets identified from human data and validated in its proprietary human iPSC models, a approach distinct from many companies targeting known genetic drivers or pathways.

More companies in Small Molecule Drugs →More companies in United States →